U.S. markets closed
  • S&P Futures

    3,903.00
    -13.25 (-0.34%)
     
  • Dow Futures

    31,386.00
    -101.00 (-0.32%)
     
  • Nasdaq Futures

    12,101.75
    -38.75 (-0.32%)
     
  • Russell 2000 Futures

    1,756.80
    -4.90 (-0.28%)
     
  • Crude Oil

    106.45
    -1.17 (-1.09%)
     
  • Gold

    1,833.60
    +3.30 (+0.18%)
     
  • Silver

    21.15
    +0.02 (+0.09%)
     
  • EUR/USD

    1.0570
    +0.0011 (+0.11%)
     
  • 10-Yr Bond

    3.1250
    +0.0570 (+1.86%)
     
  • Vix

    27.23
    -1.82 (-6.27%)
     
  • GBP/USD

    1.2288
    +0.0018 (+0.15%)
     
  • USD/JPY

    135.0530
    -0.1170 (-0.09%)
     
  • BTC-USD

    21,046.12
    -427.39 (-1.99%)
     
  • CMC Crypto 200

    462.12
    +8.22 (+1.81%)
     
  • FTSE 100

    7,208.81
    +188.36 (+2.68%)
     
  • Nikkei 225

    26,491.97
    +320.77 (+1.23%)
     

ESSA Pharma's Interim EPI-7386 Data Shows Continuous Antigen Decline In Early-Stage Prostate Cancer Study

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • ESSA Pharma Inc (NASDAQ: EPIX) has announced initial data from Phase 1 trial evaluating the company's lead candidate, EPI-7386, to treat patients with metastatic castration-resistant prostate cancer. Data were at the 2021 American Society of Clinical Oncology Genitourinary

  • Data highlights compare preclinical projections of EPI-7386's clinical pharmacokinetic parameters to the pharmacokinetic, safety, and preliminary clinical data from the initial 200 mg cohort in patients who progressed on two or more approved systemic therapies.

  • In this initial cohort, EPI-7386 was well-tolerated with no severe adverse events observed.

  • EPI-7386 was well-absorbed, demonstrated high exposure levels, and was confirmed to have a long half-life of at least 24 hours. The predicted exposures of EPI-7386 in patients were similar to modeled projections and were still below optimal target exposures of EPI-7386 associated with anti-tumor activity in animal models.

  • One out of three patients who completed 12 weeks of therapy experienced a prostate-specific antigen decline (PSA) of more than 50% after three cycles of EPI-7386 therapy (12 weeks) with ongoing continued PSA declines continuing through six cycles of therapy, despite previously having failed enzalutamide and abiraterone acetate.

  • ESSA recently completed the 28-Day safety evaluation period for the 400mg dose cohort and is currently dosing patients in the 600 mg cohort.

  • More clinical data is expected in the second half of 2021.

  • Price Action: EPIX stock gained 46% at $28.29 during market trading hours on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.